EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Somatic Mutation Detection in Tumor Tissue and Matched Cell-Free DNA Using PCR-Based Methods in Pancreatic Cancer Patients Undergoing Upfront Resection

Hana Zavrtanik Čarni iD, David Badovinac iD, Tanja Blagus iD, Katja Goričar iD, Branislava Ranković iD, Alenka Matjašič, Andrej Zupan iD, Aleš Tomažič iD, Vita Dolžan iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hana Zavrtanik Čarni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Abdominal Surgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Mutation, Carcinoma, Pancreatic Ductal, Polymerase Chain Reaction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Slovenian Research and Innovation Agency, Slovenian Research and Innovation Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic mutations in KRAS and TP53 are among the most common genetic alterations in pancreatic ductal adenocarcinoma (PDAC). Advances in PCR-based technologies now enable the detection of these mutations in tumor tissue and cell-free DNA (cfDNA), providing a minimally invasive approach to assess tumor burden. However, in resectable PDAC, circulating tumor DNA (ctDNA) may represent less than 0.1% of total cfDNA, requiring highly sensitive detection methods. The aim of our study was to assess two PCR-based assays—competitive allele-specific PCR (castPCR) and digital PCR (dPCR)—for detecting selected somatic mutations in tumor tissue, cfDNA, and extracellular vesicle-associated DNA (EV-DNA) from plasma. Matched primary tumor and preoperative plasma samples were collected from 50 patients undergoing upfront resection for PDAC. CastPCR was used for detecting selected KRAS, TP53, SMAD4, and CDKN2A mutations in tumor DNA. Additionally, dPCR was used to analyze KRAS and TP53 mutations in tumor DNA as well as cfDNA and EV-DNA. The concordance between both platforms was 71.4% for KRAS p.G12D and 58.3% for the analysis of TP53 p.R273H mutations in tumor tissue. However, dPCR detected these mutations in an additional 28.6% and 39.6% of samples, respectively. In cfDNA, dPCR identified KRAS p.G12D in 10.2% and TP53 p.R273H in 2.0% of samples. Mutation detection in EV-DNA was limited by low DNA yield. Both platforms proved effective for tumor DNA analysis, with dPCR offering greater sensitivity. Somatic mutation detection from liquid biopsy using dPCR further supports its potential utility in the preoperative setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsMutationCarcinoma, Pancreatic DuctalPolymerase Chain ReactionCirculating Tumor DNACell-Free Nucleic AcidsHumansFemaleMaleAgedMiddle AgedTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)Biomarkers, TumorDNA Mutational AnalysisSmad4 ProteinAged, 80 and over

Stichwörter der Autor:innen

cell-free DNAdigital PCRliquid biopsypancreatic cancersomatic mutation detection

Substanzen

Circulating Tumor DNATumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)KRAS protein, humanTP53 protein, humanBiomarkers, TumorCell-Free Nucleic AcidsSmad4 ProteinSMAD4 protein, human

Autor:innen und Institutionen

  • Department of Abdominal Surgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
  • Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
  • Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.

ORCID-Profile: Hana Zavrtanik Čarni, David Badovinac, Tanja Blagus, Katja Goričar, Branislava Ranković, Andrej Zupan, Aleš Tomažič, Vita Dolžan

Förderung

  • The Slovenian Research and Innovation Agency
  • Slovenian Research and Innovation Agency

Zitieren

APA

Zavrtanik Čarni, H., Badovinac, D., Blagus, T., Goričar, K., Ranković, B., Matjašič, A., Zupan, A., Tomažič, A., & Dolžan, V. (2025). Somatic Mutation Detection in Tumor Tissue and Matched Cell-Free DNA Using PCR-Based Methods in Pancreatic Cancer Patients Undergoing Upfront Resection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178518

Vancouver

Zavrtanik Čarni H, Badovinac D, Blagus T, Goričar K, Ranković B, Matjašič A, et al. Somatic Mutation Detection in Tumor Tissue and Matched Cell-Free DNA Using PCR-Based Methods in Pancreatic Cancer Patients Undergoing Upfront Resection. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178518

BibTeX
@article{Zavrtanikarni2025,
  author = {Zavrtanik Čarni, Hana and Badovinac, David and Blagus, Tanja and Goričar, Katja and Ranković, Branislava and Matjašič, Alenka and Zupan, Andrej and Tomažič, Aleš and Dolžan, Vita},
  title = {Somatic Mutation Detection in Tumor Tissue and Matched Cell-Free DNA Using PCR-Based Methods in Pancreatic Cancer Patients Undergoing Upfront Resection},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178518}
}
Kostenlos starten →